TRBC1 and mature T-cell and NK-cell non-Hodgkin lymphoma: As a pivotal proof of concept, an anti-TRBC1 chimeric antigen receptor (CAR) T cell was engineered to recognize and kill TRBC1+, but not TRBC2+, T cells in a preclinical model143 paving a path toward adoptive cellular therapy for PTCL.